Kineta, Inc. (KA)

NASDAQ: KA · IEX Real-Time Price · USD
0.525
+0.004 (0.77%)
At close: Mar 28, 2024, 4:00 PM
0.517
-0.008 (-1.56%)
After-hours: Mar 28, 2024, 7:45 PM EDT

Company Description

Kineta, Inc. is a clinical-stage biotechnology company with a focus on developing immunotherapies that transform patients' lives.

It focuses on developing potentially differentiated immunotherapies that address the challenges with current cancer therapy.

The company's immuno-oncology pipeline includes KVA12123, a VISTA blocking immunotherapy in development as a twice weekly monoclonal antibody (mAb) infusion drug.

KVA12123 is being evaluated in a Phase 1/2 clinical trial as a monotherapy and in combination with pembrolizumab in patients with advanced solid tumors, including non-small cell lung, ovarian, head and neck, renal cell, and colorectal cancers.

It is also developing anti-CD27 agonist mAb immunotherapy, which is in preclinical development for advanced solid tumors, such as renal cell carcinoma, ovarian, and colorectal cancers.

The company has collaboration and license agreements with MSD International Business GmbH, Genentech, Inc., FAIR Therapeutics B.V., and GigaGen, Inc. Kineta, Inc. was founded in 2007 and is headquartered in Seattle, Washington.

Kineta, Inc.
Kineta logo
Country United States
Founded 2007
Industry Biotechnology
Sector Healthcare
Employees 11
CEO Craig W. Philips

Contact Details

Address:
7683 Se 27th Street, Suite 481
Mercer Island, Washington 98040
United States
Phone (206) 378-0400
Website kinetabio.com

Stock Details

Ticker Symbol KA
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001445283
ISIN Number US49461C1027
SIC Code 2834

Key Executives

Name Position
Craig W. Philips President
Pauline Kenny Esq., J.D. Advisor
Keith A. Baker Chief Financial Officer
Dr. Thierry Guillaudeux Ph.D. Chief Scientific Officer
Gary Gentges Executive Vice President of Corporate Development

Latest SEC Filings

Date Type Title
Mar 21, 2024 10-K Annual Report
Mar 21, 2024 8-K Current Report
Mar 12, 2024 8-K Current Report
Feb 29, 2024 8-K Current Report
Feb 14, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Feb 12, 2024 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Feb 12, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Jan 17, 2024 8-K Current Report
Jan 5, 2024 8-K Current Report
Dec 15, 2023 8-K Current Report